Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
LACK OF INTERACTION BETWEEN RAMIPRIL AND SIMVASTATIN
Autore:
MEYER BH; SCHOLTZ HE; MULLER FO; LUUS HG; DELAREY N; SEIBERTGRAFE M; ECKERT HG; METZGER H;
Indirizzi:
UNIV ORANGE FREE STATE,DEPT PHARMACOL G6,POB 339 BLOEMFONTEIN 9300 SOUTH AFRICA HOECHST AG W-6230 FRANKFURT GERMANY
Titolo Testata:
European Journal of Clinical Pharmacology
fascicolo: 4, volume: 47, anno: 1994,
pagine: 373 - 375
SICI:
0031-6970(1994)47:4<373:LOIBRA>2.0.ZU;2-7
Fonte:
ISI
Lingua:
ENG
Soggetto:
INHIBITORS;
Keywords:
ACE-INHIBITORS; SIMVASTATIN, RAMIPRIL, LIPID LOWERING DRUGS, DRUG INTERACTION, PHARMACOKINETICS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
8
Recensione:
Indirizzi per estratti:
Citazione:
B.H. Meyer et al., "LACK OF INTERACTION BETWEEN RAMIPRIL AND SIMVASTATIN", European Journal of Clinical Pharmacology, 47(4), 1994, pp. 373-375

Abstract

Twenty two healthy males participated in a randomised, placebo-controlled, double blind, crossover study to investigate the influence of simvastatin on the pharmacokinetics of ramipril and its active metabolite (ramiprilat), and on the ACE-inhibiting effect of ramiprilat. Duringtwo study periods, each of 7 days, subjects received daily either simvastatin 20 mg at 19.00 h or placebo; ramipril (5 mg) was given on Day5 of each of the periods. Plasma concentrations of ramipril and ramiprilat and ACE-activity were measured in sequential blood specimens, and ramipril and ramiprilat concentrations were measured in urine. Bloodand urine collections for pharmacokinetic and pharmacodynamic assessment were made up to 72 h after the dose of ramipril. The mean AUC of ramipril for ramipril + placebo (R + P) and ramipril + simvastatin (R S) was 22.2 and 21.3 ng.h.ml(-1), respectively; for ramiprilat the corresponding figures were 61.3 and 57.6 ng.h.ml(-1). The urinary excretion of ramipril + metabolites for (R + P) and (R + S) was 25.2 and 24.1 % of dose. The maximum percentage inhibition of ACE-activity for (R P) was 94.6 %, and for (R + S) it was 94.1 %. It is concluded that concomitant administration of simvastatin and ramipril has no clinically relevant effect on the pharmacokinetics or ACE-inhibition of the latter drug and its metabolites.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/11/20 alle ore 06:52:17